IB
IBIO.US iBio, Inc. Common Stock
- Market cap
- USD 51.6M
- P/E
- -
- P/B
- 0.66x
- ROE
- -38.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is IBIO.US undervalued?
Graham numberThe Graham number of iBio, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
iBio, Inc. Common Stock fundamental analysis
No fundamental analysis for iBio, Inc. Common Stock yet.
iBio, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large…
Full company profileiBio, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
iBio, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 394K | 444K | 2.02M | 1.64M | 2.37M | 1.88M | 50.0K | 225K | 400K | 100K | 4.30M |
| Gross Profit | 394K | 444K | 2.02M | 935K | 909K | -1.91M | 50.0K | 225K | 400K | 100K | 4.30M |
| Operating Income | -14.3M | -14.2M | -15.8M | -14.0M | -31.1M | -29.7M | -29.3M | -16.6M | -18.6M | -35.1M | -33.4M |
| EBITDA | -12.5M | -12.5M | -13.9M | -11.7M | -28.6M | -25.7M | -28.1M | -14.0M | -17.0M | -32.0M | -30.2M |
| Net Income | -14.5M | -16.1M | -17.6M | -16.4M | -23.2M | -50.4M | -29.3M | -24.9M | -18.4M | -33.0M | -30.2M |
| EPS | -815 | -757 | -465 | -131 | -59 | -2,889 | -48 | -6.50 | -1.75 | -0.32 | -0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 36.0M | 43.1M | 30.6M | 94.2M | 147M | 99.4M | 41.2M | 28.7M | 23.2M | 99.1M | 88.7M |
| Total Liabilities | 27.1M | 26.9M | 28.1M | 37.6M | 38.4M | 35.9M | 25.8M | 7.41M | 8.31M | 13.4M | 10.1M |
| Shareholders' Equity | 8.91M | 16.2M | 2.46M | 56.6M | 109M | 63.5M | 15.4M | 21.3M | 14.9M | 85.7M | 78.6M |
| Cash & Short-term Investments | 8.09M | 15.9M | 4.42M | 55.1M | 97.0M | 33.5M | 7.33M | 14.2M | 8.58M | 88.0M | 76.7M |
| Total Debt | 25.3M | 25.1M | 24.9M | 32.9M | 32.7M | 25.8M | 17.1M | 4.46M | 3.51M | 2.20M | 2.07M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.2M | -13.5M | -14.0M | -13.3M | -30.1M | -37.5M | -30.4M | -18.6M | -15.3M | -23.2M | -37.5M |
| Capital Expenditure | 1.59M | 1.08M | 990K | 1.15M | 4.92M | 7.33M | 5.74M | 210K | 16.0K | 578K | 408K |
| Free Cash Flow | -14.8M | -14.6M | -15.0M | -14.5M | -35.0M | -44.8M | -36.2M | -18.8M | -15.3M | -23.8M | -38.0M |
| Ratios | |||||||||||
| ROE | -163.0% | -99.6% | -714.3% | -29.0% | -21.4% | -79.4% | -190.6% | -116.8% | -123.5% | -38.6% | -38.4% |
| ROA | -40.4% | -37.4% | -57.5% | -17.5% | -15.8% | -50.7% | -71.1% | -86.7% | -79.3% | -33.3% | -34.1% |
| Net Profit Margin | -3,688.3% | -3,627.3% | -871.8% | -1,003.6% | -978.8% | -2,674.7% | -58,622.0% | -11,069.8% | -4,594.3% | -33,044.0% | -702.4% |
| Debt to Equity | 2.83x | 1.55x | 10.10x | 0.58x | 0.30x | 0.41x | 1.11x | 0.21x | 0.24x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
iBio, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 500K | 0.82 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 21.6M | 172 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Nov 29, 2023.
Who owns iBio, Inc. Common Stock
- Insiders 1.25%
- Institutions 62.05%
- Public & others 36.70%
- Shares outstanding 70.5M
- Free float 50.5M
Top funds holding IBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.47M | 2.28% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 255K | 0.40% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 144K | 0.22% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 83.6K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 75.3K | 0.12% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 30.4K | 0.05% | +455.97% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 29.6K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 20.7K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 9.44K | 0.01% | +35.42% | Sep 2026 |
| JHVIT Total Stock Market Index I | 963.00 | 0.00% | 0.00% | Sep 2026 |
| Guggenheim Active Allocation Fund | 4.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding IBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 4.01M | 6.23% | +28.99% | Jun 2026 |
| Cormorant Asset Management, LLC | 3.57M | 5.55% | 0.00% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.52M | 5.47% | +1,457.74% | Jun 2026 |
| Vestal Point Capital LP | 2.60M | 4.04% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.10M | 3.26% | +92.79% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 1.95M | 3.04% | 0.00% | Jun 2026 |
| Ensign Peak Advisors Inc | 1.83M | 2.85% | 0.00% | Jun 2026 |
| Woodline Partners LP | 1.78M | 2.76% | 0.00% | Jun 2026 |
| Millennium Management LLC | 1.65M | 2.57% | +6.56% | Jun 2026 |
| Citadel Advisors Llc | 1.38M | 2.15% | +44.71% | Jun 2026 |
| Balyasny Asset Management LLC | 1.17M | 1.82% | +15.82% | Jun 2026 |
| Bank of America Corp | 1.12M | 1.74% | +286.17% | Jun 2026 |
| Ikarian Capital, LLC | 957K | 1.49% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 904K | 1.41% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 904K | 1.41% | +45.69% | Jun 2026 |
| Renaissance Technologies Corp | 688K | 1.07% | +239.37% | Sep 2026 |
| Geode Capital Management, LLC | 501K | 0.78% | +29.22% | Jun 2026 |
| Walleye Trading Advisors, LLC | 500K | 0.78% | +28.78% | Jun 2026 |
| Squarepoint Ops LLC | 499K | 0.78% | 0.00% | Jun 2026 |
| Noesis Capital Management | 405K | 0.63% | +30.02% | Jun 2026 |
iBio, Inc. Common Stock company profile
- Company name
- iBio, Inc. Common Stock
- Ticker
- IBIO.US
- Exchange
- USA Stocks
- Listed since
- Aug 19, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- June
- Address
- 11750 Sorrento Valley Road, San Diego, CA, United States, 92121
- Phone
- 979 446 0027
- Website
- ibioinc.com
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc. Common Stock management
4- Dr. Martin B. Brenner D.V.M., Ph.D.CEO, Chief Scientific Officer & Director · born 1970
- Mr. Felipe DuranCFO & Principal Accounting Officer · born 1979
- Mr. Marc Banjak J.D.Chief Legal Officer & Corporate Secretary · born 1977
- Dr. Molly Carr M.D.Chief Medical Officer · born 1967